Kamada Ltd. filings document a foreign private issuer reporting on a global biopharmaceutical business focused on specialty plasma-derived therapies and marketed products for rare and serious conditions. Recent Form 6-K reports include exhibits on financial results, annual guidance, investor presentations, product-supply tenders, and FDA approval of a plasma collection center.
The filings also record ordinary-share dividend actions, withholding-tax procedures tied to Israeli tax rules, and incorporation of certain current reports by reference into Form S-8 registration statements. Kamada files as a Form 20-F issuer, with disclosures covering governance, capital-return actions, commercial portfolio performance and regulatory events affecting plasma collection and product supply.
KAMADA LTD (KMDA) reported a 60,000-option award for VP Quality Yael Brenner, with the options held by a trustee under its 2011 Share Award Plan. The options cover 60,000 ordinary shares and have an exercise price of $7.44 per share, a convenience conversion from NIS. The exercise price was adjusted from $7.61 in connection with a special cash dividend declared by the board on August 17, 2026, with a record date of August 27, 2026. The options vest in four equal installments, 25% on each of the four grant anniversaries.
KAMADA LTD's Form 4 for director David Tsur reports two employee stock-option awards held by a trustee under the company's 2011 Share Award Plan: options covering 7,500 ordinary shares at $5.99 and 30,000 ordinary shares at $7.38. Both exercise prices were adjusted in connection with a special cash dividend declared August 17, 2026, with an August 27, 2026 record date. The options vest over four years in four equal installments, with 25% vesting on each grant-date anniversary. The U.S.-dollar prices are convenience conversions from NIS using the Bank of Israel rate as of September 22, 2026.
KAMADA LTD (KMDA) reported that Yael Brenner, Vice President of Quality, exercised employee stock options on September 14, 2026. The options covered 26,964 shares of ordinary shares at an exercise price of $5.93 per share, with the options held through a trustee under the company’s 2011 Share Award Plan.
The exercises resulted in acquisitions of ordinary shares and related dispositions where 7,395 shares were delivered or withheld to pay the option exercise price and tax withholdings, using closing share prices of about $8.36 and $8.35 per share, as described in the company’s plan footnotes.
KAMADA LTD (KMDA) reported that VP and General Counsel Nir Livneh exercised employee stock options for 10,000 ordinary shares on September 14, 2026 at an exercise price of $5.37 per share. This was a net exercise: Livneh received 3,459 shares after the company withheld 6,541 shares to cover the exercise price and tax withholdings, using the $8.35 closing stock price on that date. No Rule 10b5-1 trading plan is reported.
KAMADA LTD (KMDA) director David Tsur reported a sale of 22,827 Ordinary Shares on September 14, 2026, at a price of $8.18 per share, which reflects a convenience conversion from NIS using the Bank of Israel rate that day. Following this open-market sale, he holds 407,929 Ordinary Shares directly, and no Rule 10b5-1 trading plan is reported for this transaction.
Kamada Ltd. (KMDA) reports that it has sufficient KedRAB human rabies immune globulin inventory and manufacturing capacity to meet increased demand in the United States. This follows a U.S. CDC Health Advisory on a significant nationwide year-over-year rise in human rabies exposures and rabies post-exposure prophylaxis use.
KedRAB, developed and manufactured by Kamada and supplied in the U.S. through Kedrion Biopharma Inc., is one of only two FDA-approved anti-rabies immunoglobulin products indicated for post-exposure prophylaxis. Kamada cites its vertically integrated supply chain, long-standing partnership with Kedrion, and recent FDA approval of its in-house rabies testing lab as positioning it to support higher demand while maintaining product quality and consistency.
The company notes CDC estimates that about 1.4 million people in the U.S. seek care annually for possible rabies exposure, with roughly 100,000 receiving post-exposure prophylaxis, and it estimates the total U.S. market for rabies immunoglobulin products at approximately $200 million per year. Kamada reiterates a growth strategy based on expanding its plasma-derived product portfolio, in-licensing in Israel and MENA, scaling plasma collection, and pursuing acquisitions and collaborations.
KAMADA LTD (KMDA) director David Tsur reported open‑market sales of a total of 177,173 Ordinary Shares over three days in September 2026. He sold 14,238 shares on September 7 at $8.28, 162,760 shares on September 8 at $8.26, and 175 shares on September 9 at $8.26. The U.S. dollar prices are convenience conversions from New Israeli Shekels based on Bank of Israel exchange rates for each respective date, and no Rule 10b5‑1 trading plan is reported.
Kamada Ltd. (KMDA), a global biopharmaceutical company focused on specialty plasma-derived therapies for rare and serious conditions, reports that CEO Amir London will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 15, 2026, at 2:30 p.m. Eastern Time. A live webcast and 30-day replay will be available through the company’s website. Kamada describes a growth strategy built on four pillars: expanding its commercial portfolio of specialty plasma-derived and equine-based products, distributing third-party pharmaceuticals (including biosimilars) in Israel and the MENA region, ramping up U.S. plasma collection operations, and pursuing mergers, acquisitions, and collaborations to enhance its marketed portfolio.
Kamada Ltd. (KMDA) filed a Form F-3 shelf registration to offer and sell from time to time up to $50,000,000 of ordinary shares. The ordinary shares trade on Nasdaq Global Select Market and the Tel Aviv Stock Exchange under the symbol KMDA, with recent prices of $8.54 and NIS 24.91 ($8.27) per share, respectively.
Kamada is a global biopharmaceutical company focused on specialty plasma-derived therapies and distribution of in-licensed products in Israel and the MENA region. Proprietary Products segment sales were $156.2 million in 2025, up from $141.4 million in 2024 and $115.5 million in 2023, led by KEDRAB, GLASSIA and a CMV immunoglobulin product that together generated about half of 2025 revenues and around 70% of gross profitability. The Distribution segment generated $24.3 million of revenue in 2025.
The company highlights growth initiatives including a three-year $50 million normal source plasma supply agreement expected to begin generating sales in the fourth quarter of 2026, expansion of biosimilar distribution in Israel, and additional M&A and in-licensing opportunities. Net proceeds from any offerings under this shelf are expected to be used for general corporate purposes, with specific terms and pricing to be set in future prospectus supplements.